Activists take India’s patent office to court over Gilead’s hepatitis C drug

The United States-based not-for-profit group, Initiative for Medicines, Access & Knowledge (I-MAK) and the human rights group, Delhi Network of Positive People (DNP+), have together filed a writ in the Delhi High Court to challenge the Indian government's recent decision of granting patent to a costly hepatitis C drug. The drug, called sofosbuvir, is one of the costliest medicines in the world, priced at $1,000 per pill in the U.S. by its manufacturer ...

Patent Challenge Hearing on Gilead Hepatitis C Drug Sofosbuvir Starts in India

New York/New Delhi—In proceedings that could have major implications for millions of people waiting for affordable access to a lifesaving hepatitis C drug, the Indian Patent Office this week began hearings to determine whether US pharmaceutical company Gilead Sciences deserves a patent for sofosbuvir, a hepatitis C drug for which the company currently charges $1,000 per pill in the US.Today’s hearings are in relation to a "patent opposition" filed by lawye

Middle-Income Countries consider voiding hepatitis C drug patents

Physician, patient, and health justice groups including the Initiative for Medicines, Access and Knowledge (I-MAK) are mounting legal challenges to Gilead Sciences' patent to sofosbuvir in several middle-income countries including Argentina, Brazil, China, Russia and Ukraine. Read more...http://www.nytimes.com/2015/05/20/business/high-cost-of-hepatitis-c-drug-prompts-a-call-to-void-its-patents.html...